Evaluation of the efficacy of Er,Cr:YSGG laser in Treating oral benign soft tissue lesions.

Background: Managing benign oral soft tissue lesions presents a clinical challenge, often requiring invasive procedures with associated drawbacks. The Er,Cr:YSGG laser has emerged as a potential solution, given its precision and minimal tissue disruption in other medical contexts. Methods: This pre-post study involved 16 participants diagnosed with benign oral soft tissue lesions. The lesions were excised using the Er,Cr:YSGG laser (2780 nm) with 2.75‒3.75-W power outputs. Pain was quantified using a numerical rating scale from 0 to 10, and edema presence was noted. Function interference and satisfaction were graded. Healing was assessed via the Early Wound Healing Score (EHS). The observation spanned three postoperative intervals: day 1, day 3, and day 7. Results: This study included 16 participants with benign oral soft tissue lesions, predominantly pyogenic granuloma and fibroepithelial polyp. Initial discomfort and bleeding were common, while a small proportion reported pain. Er,Cr:YSGG laser treatment significantly reduced discomfort (VAS score) and promoted healing (EHS score) over time. Function interference decreased, and patient satisfaction improved from day 1 to day 7. Additionally, bleeding scores decreased drastically, confirming the laser's effective hemostatic properties. Conclusion: The findings suggest that Er,Cr:YSGG laser treatment presents a promising, less invasive approach for managing oral benign soft tissue lesions, prioritizing patient well-being and contentment alongside successful lesion removal.